Showing 4541-4550 of 5771 results for "".
- First Patient Dosed in Phase 3 Clinical Trial of Dextenza for the Treatment of Post-Surgical Ocular Inflammation and Pain in Childrenhttps://modernod.com/news/ocular-therapeutix-announces-first-patient-dosed-in-phase-3-clinical-trial-of-dextenza-for-the-treatment-of-post-surgical-ocular-inflammation-and-pain-in-children/2478274/Ocular Therapeutix announced that it has dosed the first patients in a phase 3 clinical trial of Dextenza (dexamethasone ophthalmic insert) 0.4 mg for the treatment of post-surgical ocular inflammation and pain in children following cataract surgery. “We are pleased to announce the start o
- AstraZeneca Resumes COVID-19 Vaccine Trialshttps://modernod.com/news/astrazeneca-resumes-covid-19-vaccine-trials/2478273/AstraZeneca announced that clinical trials of its experimental COVID-19 vaccine AZD1222 have resumed in the UK following confirmation by the Medicines Health Regulatory Authority (MHRA) that it was safe to do so. “On 6 September, the standard review process triggered a voluntary pause to va
- Aura Biosciences Doses First Patient in Phase 2 Study Evaluating Suprachoroidal Administration of AU-011 in Patients with Choroidal Melanomahttps://modernod.com/news/aura-biosciences-doses-first-patient-in-phase-2-study-evaluating-suprachoroidal-administration-of-au-011-in-patients-with-choroidal-melanoma/2478272/Aura Biosciences announced the dosing of the first patient in a phase 2 study evaluating the safety and efficacy of suprachoroidal (SC) administration of AU-011, the company’s lead product candidate, as a potential first-line treatment for patients with primary choroidal melanoma. “I am ho
- Kala Pharmaceuticals to Host Key Opinion Leader Symposium on Unmet Need in Dry Eye Disease and Potential for Eysuvishttps://modernod.com/news/kala-pharmaceuticals-to-host-key-opinion-leader-symposium-on-unmet-need-in-dry-eye-disease-and-potential-for-eysuvis/2478270/Kala Pharmaceuticals announced that it will host a key opinion leader symposium on the unmet need in dry eye disease and the potential for Eysuvis as a short-term treatment for the signs and symptoms of the disease. The event will be held virtually on Thursday, September 17, 2020, beginning at 8
- Clearside Biomedical’s Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjectorhttps://modernod.com/news/clearside-biomedicals-partner-doses-first-patient-in-its-phase-2-study-in-patients-with-choroidal-melanoma-using-scs-microinjector/2478269/Clearside Biomedical announced that its licensing partner, Aura Biosciences, has dosed the first patient in its phase 2 clinical trial evaluating the safety and efficacy of suprachoroidal administration of AU-011 as a potential first-line treatment for patients with primary choroi
- HelpMeSee Names Saro Jahani As President and CEOhttps://modernod.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/Nonprofit HelpMeSee announced the appointment of Saro Jahani as President and CEO. He will also join the Board of Directors. Mr. Jahani succeeds Jacob Mohan Thazahathu, who retired after 10 years of service. Mr. Jahani
- Visible Genomics Launches DNA Age-Related Macular Degeneration Testinghttps://modernod.com/news/visible-genomics-launches-dna-age-related-macular-degeneration-testing/2478264/Visible Genomics, a Chicago-area genetics testing company, has announced the launch of a new noninvasive genetic eye test that the company says determines a patient’s likelihood of contracting age-related macular degeneration (AMD). While it’s estimated that up to 70% of AMD cases are due
- Zeiss Launches New Frame and Lens Disinfecting Technology to Support Safety and Hygiene in Eye Care Practiceshttps://modernod.com/news/zeiss-launches-new-frame-and-lens-disinfecting-technology-to-support-safety-hygiene-and-productivity-in-eyecare-practices/2478262/Zeiss Vision Care US announced the launch of the
- Sight Sciences Presents Additional Results of OLYMPIA Study of Signs and Symptoms of Dry Eye Disease Using TearCarehttps://modernod.com/news/sight-sciences-presents-additional-results-of-olympia-study-of-signs-and-symptoms-of-dry-eye-disease-using-tearcare/2478263/Sight Sciences announced further favorable results of a trial evaluating a single treatment of TearCare for the treatment of signs and symptoms of dry eye disease in patients with meibomian gland dysfunction. TearCare is currently marketed for the application of localized heat to the eyelids for
- The Vision Council Launches New Brand Identity and Member-Focused Websitehttps://modernod.com/news/the-vision-council-launches-new-brand-identity-and-member-focused-website/2478260/The Vision Council announced the launch of a new brand identity, including a reimagined logo and a new website designed to better serve and accommodate the needs of members and the vision care community at large. The rebrand and website launch represent the initial phase of the plan The Vision Co